- Home »
- Quarterly Results »
- Morepen Laboratories Q1 Results Reported Revenue of ₹45,521.57 Lakhs and Improved Net Profit After Tax of ₹3,616.79 Lakhs
Morepen Laboratories Q1 Results Reported Revenue of ₹45,521.57 Lakhs and Improved Net Profit After Tax of ₹3,616.79 Lakhs
Morepen Laboratories Q1 Results reveal a total income of ₹45.89 Cr. with a QoQ increase of 7.6%, an operating profit margin of 10.08%, and a profit after tax of ₹3,616.79 lakhs, marking a 26% QoQ growth.
by P Nandhini
Updated Sep 28, 2024
Table of Content
Morepen Laboratories Q1 Results: Morepen Laboratories declared their Q1 results for the financial year 2024-2025, showing a solid performance with a 7.6% quarter-on-quarter (QoQ) increase in revenue, from ₹42,307.35 lakhs in Q4 2023-2024 to ₹45,521.57 lakhs in Q1.
The company also saw a YoY growth of 12% compared to the same period last year, highlighting steady demand across its product lines. Other income, however, decreased slightly QoQ from ₹424.30 lakhs to ₹342.70 lakhs.
Overall, total income for Q1 stood at ₹45,864.27 lakhs, marking an improvement from the previous quarter’s ₹42,731.65 lakhs. On the expenditure front, Morepen Laboratories reported total expenses rising by 6.6% QoQ to ₹41,047.66 lakhs, with notable increases in material costs and stock purchases.
Despite this, the company's profit before tax (PBT) increased by 14.1% QoQ, reaching ₹4,816.61 lakhs, and net profit after tax surged by 26% QoQ to ₹3,616.79 lakhs. The earnings per share (EPS) improved to ₹0.71, up from ₹0.54 in the previous quarter, showcasing the company’s growing profitability in the current fiscal year.
For More Q1 results check our Twitter Page
Morepen Laboratories Q1 Results 2024 - 2025
Morepen Laboratories has released its Q1 results for the financial year 2024-2025, showing a strong performance across key financial metrics. The company witnessed both quarter-on-quarter (QoQ) and year-over-year (YoY) improvements in revenue and profitability. Below is a summary of the key financial figures for Q1 2024-2025:
| Particulars | Q1 FY 2024-25 (₹ in Lakhs) | Q4 FY 2023-24 (₹ in Lakhs) |
|---|---|---|
| Income from Operations (Net) | 45,521.57 | 42,307.35 |
| Other Income | 342.70 | 424.30 |
| Total Income | 45,864.27 | 42,731.65 |
| Cost of Material Consumed | 23,501.46 | 22,026.28 |
| Purchase of Stock-in-Trade | 5,597.43 | 3,008.46 |
| Changes in Inventories | (817.75) | 617.65 |
| Employee Benefits Expenses | 4,795.52 | 4,794.35 |
| Total Expenditure | 41,047.66 | 38,511.47 |
| Profit Before Tax (PBT) | 4,816.61 | 4,220.18 |
| Tax Expense | 1,199.82 | 1,346.08 |
| Net Profit After Tax | 3,616.79 | 2,874.10 |
| Other Comprehensive Income (OCI) | 257.15 | (203.46) |
| Total Comprehensive Income | 3,873.94 | 2,624.60 |
| Earnings Per Share (EPS) (₹) | 0.71 | 0.54 |
| Paid-up Equity Share Capital (₹) | 10,222.71 | 10,222.71 |
Source: Click Here
Morepen Laboratories Current Market Overview
Morepen Laboratories is currently trading at ₹86.8 per share, with a slight increase of 0.42%. The company has a market value of ₹4,757 crore and has seen its stock price fluctuate between a high of ₹101 and a low of ₹31.3 over the past year.
It has a price-to-earnings ratio of 40.4, showing that investors are paying 40 times its earnings per share. Despite not offering any dividends, the company has strong returns, with a return on capital employed (ROCE) of 16.8% and a return on equity (ROE) of 12%.
| Metric | Value |
|---|---|
| Current Price | ₹86.8 |
| Price Change | +0.42% |
| Market Cap | ₹4,757 crore |
| Price-to-Earnings (P/E) | 40.4 |
| Book Value | ₹16.6 |
| Dividend Yield | 0.00% |
| Return on Capital Employed (ROCE) | 16.8% |
| Return on Equity (ROE) | 12.0% |
| Face Value | ₹2.00 |
Quarterly Results
Here are the recent quarterly results for Morepen Laboratories for December 2023, March 2024, and June 2024.
| Indicator | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|
| Sales (₹ Crores) | 445 | 423 | 455 |
| Expenses (₹ Crores) | 394 | 375 | 404 |
| Operating Profit (₹ Crores) | 51 | 48 | 52 |
| Operating Profit Margin (OPM %) | 11% | 11% | 11% |
| Net Profit (₹ Crores) | 32 | 29 | 36 |
| Earnings Per Share (EPS ₹) | 0.63 | 0.55 | 0.71 |
| Change in Sales (QoQ) | - | -4.9% | +7.5% |
| Change in Net Profit (QoQ) | - | -9.4% | +24.1% |
About Morepen Laboratories
Morepen Laboratories is an Indian pharmaceutical company that was founded in 1984. The company is involved in the manufacturing, development, and marketing of a wide range of healthcare products, including active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products.
Morepen is known for producing APIs like Atorvastatin, Montelukast, and Sitagliptin, which are used globally. The company also exports its products to over 80 countries. With a strong focus on research and development, Morepen aims to deliver high-quality healthcare solutions while also maintaining a commitment to corporate social responsibility.
Check our website for more Q1 results.
Morepen Laboratories Q1 Results - FAQs
1. What are the recent Q1 results for Morepen Laboratories?
Morepen Laboratories reported a total income of ₹45,864.27 lakhs for Q1 FY 2024-2025.
2. How much did Morepen Laboratories' revenue increase QoQ?
Morepen Laboratories experienced a 7.6% QoQ increase in revenue.
3. What was the year-over-year growth for Morepen Laboratories?
Morepen Laboratories showed a YoY growth of 12% compared to the same quarter last year.
4. What is the net profit after tax for Morepen Laboratories in Q1?
Morepen Laboratories reported a net profit after tax of ₹3,616.79 lakhs.
5. What was the total expenditure for Morepen Laboratories in Q1?
Morepen Laboratories reported total expenditure of ₹41,047.66 lakhs.
6. What was the earnings per share (EPS) for Morepen Laboratories in Q1?
Morepen Laboratories had an EPS of ₹0.71 in Q1.
7. How much did Morepen Laboratories pay in tax expenses?
Morepen Laboratories' tax expense for Q1 was ₹1,199.82 lakhs.
8. What is the trend in the profit before tax for Morepen Laboratories?
Profit before tax for Morepen Laboratories increased by 14.1% QoQ.
9. What was the comprehensive income for Morepen Laboratories in Q1?
The total comprehensive income for Morepen Laboratories was ₹3,873.94 lakhs.
10. How much did Morepen Laboratories earn in other comprehensive income?
Morepen Laboratories earned ₹257.15 lakhs in other comprehensive income.